Welcome to our dedicated page for Altimmune news (Ticker: ALT), a resource for investors and traders seeking the latest updates and insights on Altimmune stock.
Altimmune, Inc. develops pemvidutide, a late clinical-stage dual-action therapy targeting glucagon and GLP-1 receptors for serious liver diseases. Company news centers on pemvidutide development in metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD) and alcohol-associated liver disease (ALD), including clinical trial updates and FDA designations such as Fast Track and Breakthrough Therapy Designation where granted.
Altimmune updates also cover financial results, business updates, investor conference participation and capital actions used to fund development activity. Recurring financing news includes public offerings, registered direct offerings, common stock, pre-funded warrants and common stock warrants.
Altimmune, Inc. (Nasdaq: ALT) reported financial results for Q1 2020, highlighting revenue of $2.2 million down from $3 million year-over-year due to reduced contract billings. R&D expenses surged to $7.2 million compared to $3.2 million in the prior year, driven by IND-enabling studies. The net loss was $3.9 million or ($0.26) per share. Notably, the company commenced preclinical testing of COVID-19 vaccine AdCOVID and plans to launch clinical trials for NasoShield and ALT-801 later in the year, aiming for a data-rich 2020.
Altimmune, a clinical-stage biopharmaceutical company, announced the appointment of Diane Jorkasky, M.D. to its Board of Directors, expanding the board to eight members. Dr. Jorkasky brings extensive experience in drug development across various therapeutic areas. CEO Vipin K. Garg expressed excitement over her contributions to Altimmune's ongoing liver disease and vaccine programs. Dr. Jorkasky emphasized the company's potential impact on public health. Her background includes leadership roles in major pharmaceutical firms, underscoring the breadth of knowledge she brings to the team.